Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 275 clinical trials
Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)

combined with docetaxel and cisplatin) and group two (docetaxel and cisplatin). - The serum concentrations of Endostatin,VEGF and bFGF are determined. - Blood circulating endothelial

neutrophil count
stage iv non-small cell lung cancer
tumor angiogenesis
cancer
docetaxel
  • 11 views
  • 07 Nov, 2020
  • 1 location
Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Comparing time to recurrence of macular edema after an initial loading dose of at least three monthly anti VEGF injections (aflibercept or ranibizumab) for macular edema in BRVO.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

although there is no consensus about the best approach. Laser can be performed on leaky aneurysms with questionable long term efficacy and potential irreversible adverse effects. Recently, anti-VEGF agents

  • 0 views
  • 02 Jul, 2021
  • 1 location
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

activity as a second-line agents (3,4). Thus, there is a necessity to identify new agents with activity to improve therapy for patients with advanced STS. In some studies, most STS showed VEGF

neutrophil count
immunomodulators
anthracyclines
doxorubicin
measurable disease
  • 13 views
  • 07 Nov, 2020
  • 1 location
Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX)

Nowadays, steroids and anti-VEGF are the first line treatment for diabetic macular edema. Ozurdex is the most frequently used steroid and has label for both first and second line treatment

  • 0 views
  • 18 Apr, 2021
  • 20 locations
25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

-VEGF) can be used as an adjuvant therapy which can make operation more easy.

vitreous hemorrhage
adjuvant therapy
type 2 diabetes mellitus
visual loss
detachment
  • 5 views
  • 22 Jan, 2021
  • 1 location
Intravitreal Bevacizumab for Retinal Disorders

Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal

other retinal disorders
macular edema
diabetic macular edema
vitreous hemorrhage
macugen
  • 23 views
  • 07 Nov, 2020
  • 1 location
Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

. plasma biomarker study (HGF, VEGF-A, VEGF-D, IFN-, Angiopoietin-2, sICAM-1, sVCAM-1, TIMP-1, PIGF (HS), IL-6 (HS), IL-8 (HS), sNeuropilin-1, Thrombospondin-2 , Osteopontin , sVEGFR1, sVEGFR2, sVEGFR3

  • 0 views
  • 29 Mar, 2021
  • 1 location
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.

. Previous studies showed that antiangiogenic treatments such as anti-VEGF treatment (bevacizumab) administered intravenously was efficient on epistaxis and dramatically reduced nosebleeds. Tyrosine

  • 0 views
  • 27 Jan, 2021
  • 10 locations
Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC

new chemotherapeutic regimen for CCRT. In previous prospective studies, investigators used proximal ligation assay technology to identify serum VEGF-A in correlation with the pathological

  • 0 views
  • 23 Jan, 2021
  • 1 location